Table 1.
Variables | N (%) | |
Patient-related | Number | 101 |
Age (y) | ||
Median | 26.0 | |
Range | 17–30 | |
Gender | ||
Male | 48 (47.5) | |
Female | 53 (52.5) | |
Marital status | ||
Married | 78 (77.2) | |
Unmarried | 23 (22.8) | |
Family history of tumor | ||
Yes | 2 (2.0) | |
No | 99 (98.0) | |
Comorbidity | ||
Yes | 6 (5.9) | |
No | 95 (94.1) | |
H.pylori | ||
+ | 7 (6.9) | |
− | 80 (79.2) | |
unknown | 14 (13.9) | |
Fibrinogen (g/L) | ||
Median | 3.13 | |
Range | 1.45–17.6 | |
Prealbumin (mg/L) | ||
Median | 205.0 | |
Range | 41.0–390.0 | |
AFP (ng/mL) | ||
Median | 2.65 | |
Range | 0.5–219.86 | |
CEA (ng/mL) | ||
Median | 2.06 | |
Range | 0.2–213.22 | |
Tumor-related | Location | |
Cardia | 7 (6.9) | |
Body | 43 (42.5) | |
Antrum | 44 (43.5) | |
Cardia + Body + Antrum | 2 (2.0) | |
Others | 5 (5.0) | |
Tumor size (cm) | ||
0–2 | 12 (11.9) | |
2–5 | 41 (40.5) | |
5–7 | 24 (23.8) | |
>7 | 24 (23.8) | |
T stage | ||
1a | 4 (4.0) | |
1b | 3 (3.0) | |
2 | 15 (14.9) | |
3 | 18 (17.8) | |
4a | 46 (45.4) | |
4b | 15 (14.9) | |
N stage | ||
0 | 29 (28.7) | |
1 | 47 (46.5) | |
2 | 19 (18.8) | |
3 | 6 (6.0) | |
M stage | ||
0 | 80 (79.3) | |
1 | 31 (30.7) | |
TNM | ||
IA | 7 (6.9) | |
IB | 4 (4.0) | |
IIA | 11 (10.9) | |
IIB | 17 (16.8) | |
IIIA | 21 (20.8) | |
IIIB | 7 (6.9) | |
IIIC | 3 (3.0) | |
IV | 31 (30.7) | |
Differentiation of the tumor | ||
Well differentiated | 10 (9.9) | |
Moderately differentiated | 18 (17.8) | |
Poorly differentiated | 73 (72.3) | |
WHO type | ||
adenocarcinoma | 67 (66.3) | |
Signet ring | 7 (7.0) | |
Adenocarcinoma & Signet ring | 18 (17.8) | |
Others | 9 (8.9) | |
Treatment-related | Surgical appoach | |
Laparotomy | 38 (37.6) | |
Laparoscope | 63 (62.4) | |
Surgical treatment | ||
Curative | 64 (63.4) | |
Palliative | 37 (36.6) | |
Treatment | ||
Surgery | 35 (34.6) | |
Surgery + chemotherapy | 64 (63.4) | |
Lost to follow-up after surgery | 2 (2.0) |
AFP = alpha-fetoprotein, CEA = carcinoembryonic antigen, H.pylori = Helicobacter pylori.